Market Pulse
Retail shares ripped higher after Macy’s delivered a surprise earnings beat, fueling a broad rally even as outlooks remain mixed.
Key Movers
Macy’s exceeded low expectations, GameStop closed notably higher ahead of its report, and XRP traders piled in after a $1.50 breakout sparked a classic short squeeze.
Macro & Politics
Regulators are circling AI-driven charting tools under the guise of investor protection, and FDA filings—like 60 Degrees’ chestnut extract notification—could face holdups.
What’s Next
Keep an eye on Fennec Pharmaceuticals’ full-year 2025 results on March 24 for a potential biotech catalyst.
Market Commentary
📈 Breaking Financial News
XRP Liquidations Accelerate After $1.50 Breakout: Short Squeeze Unfolds
XRP has reclaimed the $1.50 level as market activity accelerates and bullish momentum begins to build after weeks of consolidation. The move higher suggests that buyers are regaining control, with traders closely watching whether XRP can sustain this breakout…
Macy's stock pops as earnings beat low expectations, uncertainty clouds outlook – Yahoo Finance
Macy's stock pops as earnings beat low expectations, uncertainty clouds outlookYahoo Finance Macy's store revamp shows progress, but company expects sales to fall this yearCNBC Macy’s Same-Store Sales Boosted by Bloomingdale’s While Guidance MixedWSJ Macy’s p…
Large Bitcoin Shorts Cluster Between Current Price And $76,300 – Here’s What To Expect
A sudden rebound has shifted the market into a bullish state once again, and Bitcoin is slowly trending upward. As Bitcoin’s price momentum begins to recover, pushing it back into the $70,000 threshold, derivatives data indicate that the flagship asset is nea…
Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered …
Why EBR, EOS, Racura, and Woodside shares are rising today
These shares are avoiding the market selloff. The post Why EBR, EOS, Racura, and Woodside shares are rising today appeared first on The Motley Fool Australia.
Wall St Legend: AGI Arrives Q1 2026. The Power Grab Started Months Ago. While retail buys Nvidia at all-time highs, institutions position into something else.
Click here for the full story.
🔍 Market Analysis & Insights
Ever Joint Claims Evaluated: What the Science Says About EverJoint Joint Support Ingredients
Company-issued report examining Ever Joint ingredient research, dosing transparency, oxidative stress claims, and consumer verification steps….
SnoreStop Throat Spray Claims Evaluated: Effective Anti-Snoring Oral Solution with Clinically Proven Ingredients
SnoreStop Throat Spray claims evaluated: doctor-developed homeopathic oral spray, cited clinical study, 30-year market history, pricing reviewed…
Red Boost Claims Evaluated: The Male Performance Powder Under Investigation
Red Boost claims evaluated in 2026 report covering ingredient dosages, smooth muscle positioning, published research context, and pricing terms….
The Memory Wave Under Investigation: The 12-Minute Gamma Brain Activation Sound Session
Memory Wave under investigation: Binaural Technologies outlines gamma audio claims, pricing, refund terms, and what consumers can verify….
GameStop (GME) Stock Closes Higher at $23.59 Amid Steady Trading and Upcoming Earnings Report
GameStop Corp. (NYSE: GME) shares rose modestly on Tuesday, closing at $23.59, up $0.31 or 1.33% from the previous session's close.
Something doesn't add up. Jobs that “existed”… didn't in reality. The government deploying record AI spending. Yet Buffett holds $344B cash—his largest position EVER.
Click here to see where the money is going. Not AI stocks.
💰 Investment Opportunities
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy….
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 fin…
Navigating the regulatory pitfalls of AI charting
AI charting tools bring key workflow advantages for clinicians as well as possible regulatory pitfalls.
Blood Sugar Harmony Liquid Drops Ingredients Disclosed: Complete Details Revealed
SugarHarmony Research discloses ingredient references and scientific citations for Blood Sugar Harmony Liquid Drops, detailing 32 cited compounds….
DentaBiome Claims Evaluated: 2026 Oral Postbiotic Consumer Warning Report Issued
2026 consumer awareness report: DentaBiome 30-second kitchen method claims, oral postbiotic positioning, FabM research context evaluated….
Everyone’s fixated on Macy’s and that XRP squeeze, but they’re missing the fucking FDA play that could knock the wind out of pharma swings. 60 Degrees Pharmaceuticals’ chestnut extract NDIN filing (GlobeNewswire) and Vesicor’s Michael Tolentino appointment (GlobeNewswire) set up a regulatory showdown. One delay could torch a rally faster than any retail beat.
Combine the AI charting crackdown (Techtarget) with crypto’s crowded shorts in Bitcoin (Bitcoinist) and you’ve got regulators itching to reassert control over data and platforms once they smell money. As brokers rethink their feeds, next week’s Bitcoin moves and GameStop’s earnings report will feel that squeeze under an extra microscope.
If you’re loading up on retail momentum or riding the crypto wave, do yourself a favor—hedge with options or clip your exposure before these regulatory storms hit. And circle March 24: Fennec’s report (GlobeNewswire) could hand you a fresh entry or an exit signal. Play smart, don’t play hero.